0001213900-24-022411.txt : 20240314 0001213900-24-022411.hdr.sgml : 20240314 20240314093809 ACCESSION NUMBER: 0001213900-24-022411 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240313 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240314 DATE AS OF CHANGE: 20240314 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tenon Medical, Inc. CENTRAL INDEX KEY: 0001560293 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 455574718 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41364 FILM NUMBER: 24748164 BUSINESS ADDRESS: STREET 1: 104 COOPER CT. CITY: LOS GATOS STATE: CA ZIP: 95032 BUSINESS PHONE: (408) 649-5760 MAIL ADDRESS: STREET 1: 104 COOPER CT. CITY: LOS GATOS STATE: CA ZIP: 95032 8-K 1 ea0201769-8k_tenonmed.htm CURRENT REPORT
false 0001560293 0001560293 2024-03-13 2024-03-13 0001560293 TNON:CommonStockParValue0.001PerShareMember 2024-03-13 2024-03-13 0001560293 TNON:WarrantsMember 2024-03-13 2024-03-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):

March 13, 2024

 

TENON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41364   45-5574718
(State or other jurisdiction   (Commission File Number)  (IRS Employer
of incorporation)     Identification No.)

 

104 Cooper Court    
Los Gatos, CA   95032
(Address of principal executive offices)   (Zip Code)

 

(408) 649-5760

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   TNON   The Nasdaq Stock Market LLC
Warrants   TNONW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On March 12, 2024, Tenon Medical, Inc. (the “Company”) issued a press release announcing its earnings for the fourth quarter ended December 31, 2023 and the fiscal year ended December 31, 2023. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information set forth under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statement and Exhibits.

 

(d)Exhibits.

 

Exhibit No.   Description
99.1   Press Release dated as of March 12, 2024.
104   Cover Page Interactive Data File (formatted in Inline XBRL).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 13, 2024 TENON MEDICAL, INC.
     
  By: /s/ Steven M. Foster
  Name:  Steven M. Foster
  Title: Chief Executive Officer and President

 

 

2

 

 EX-99.1 2 ea020176901ex99-1_tenonmed.htm PRESS RELEASE DATED AS OF MARCH 12, 2024

Exhibit 99.1

 

Tenon Medical Reports Fourth Quarter and Full Year 2023 Financial Results

 

~ Fourth Quarter 2023 Revenue Increased 192% Year-Over-Year ~

 

~ Full Year 2023 Revenue Increased 324% Year-Over-Year ~

 

~ Surgical Procedures Increased 179% Year-Over-Year in the Fourth Quarter and 312% for the Full Year 2023 ~

 

~ Achieved Three Consecutive Quarters of Positive Gross Profit Margin in 2023 ~

 

~ Catamaran® SI Joint Fusion System Included in a Series of Immersive Physician Webinar Training

Programs Attended by Sixty Healthcare Providers in Q4 ~

 

Los Gatos, CA – March 12, 2024 - Tenon Medical, Inc. (NASDAQ: TNON) (“Tenon Medical” or the “Company”), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today reported financial results for the fourth quarter and full year ended December 31, 2023.

 

Fourth Quarter & Full Year 2023 and Subsequent Highlights

 

●Revenue of $808,000 in the fourth quarter of 2023, a 192% increase over the prior year quarter.

 

●Revenue of $2.9 million in 2023, a 324% increase from the full year of 2022.

 

●Gross profit increased to $1.2 million as compared to a gross loss of ($641,000) in the full year of 2022.

 

●Gross profit margin of 69% in the fourth quarter of 2023, a notable increase as compared to 57% in Q3 2023.

 

●312% increase in the number of surgical procedures in which the Catamaran System was used compared to the prior year.

 

●Participated in a series of immersive physician webinar training programs featuring the Company’s Catamaran® SI Joint Fusion System in Q4.

 

●Subsequent to year end, Tenon issued approximately $3.85 million of Series A Preferred Stock raising approximately $2.6 million in gross proceeds and retiring $1.25 million in secured debt.

 

Steve Foster, President and Chief Executive Officer of Tenon Medical, commented, “Tenon’s strong fourth quarter and full year of 2023 was underscored by solid momentum in revenue, gross profit and gross margin, with fourth quarter’s solid performance driven by a 312% year-over-year increase in surgical procedures utilizing The Catamaran System. In tandem, fourth quarter revenue increased 192% to $0.8 million, and full year 2023 achieved a 324% revenue increase to $2.9 million from 2022. Our notable achievement of three consecutive quarters of positive gross profit resulted in full year 2023 gross profit of $1.2 million and is a key performance metric we utilize for internal goal setting. Gross margin followed as well, achieving 69% in the fourth quarter, a striking sequential increase from 57% in Q3 2023.

 

Our results throughout 2023, our first full year of commercialization, were driven by the successes of our sales and marketing team, and a cadence of targeted physician workshop activities including a fourth quarter webinar series attracting over sixty healthcare providers interested in the simple inferior-posterior implantation technique of our unique transfixing SI joint implant. For the full year, we hosted 133 physicians in Catamaran focused training sessions.

 

 

 

 

Additionally, throughout 2023, we successfully secured capital that has positioned our balance sheet to support our accelerated sales and marketing initiatives to advance the commercialization of the Catamaran System. We are appreciative of the confidence in our SI products as represented by our supportive and prominent investor syndicate. Importantly, our $1.25 million secured note financing led by Ascent Special Ventures in November 2023 has been fully repaid with the issuance in February 2024 of Series A Preferred Stock to the investors in such financing.”

 

Mr. Foster continued, “Moving into 2024, we will leverage all we’ve learned in our first full year of commercialization by listening intently to our physician customers. Additionally, we will expand our educational activities to encompass the full suite of applications of our unique technology and we will continue to refine our instrument and implant offerings. We continue to make progress on our post-market multi-center study and expect a preliminary glimpse of this important data in the coming weeks.

 

Over the long-term, our goal is to further expand our product portfolio to address SI Revision with our innovative patent protected technology. Taken together, we are proud of our 2023 accomplishments including the revenue ramp and attractive gross profit from increased awareness and adoption of The Catamaran System. We’ve positioned Tenon’s balance sheet and operating structure to drive continued revenue growth in 2024 as we continue to pursue a long-term value proposition for all stakeholders,” concluded Foster.

 

Fourth Quarter & Full Year 2023 Financial Results

 

Revenue was $808,000 in the fourth quarter of 2023, an increase of 192%, compared to $277,000 in the comparable year ago period. Revenue was $2.9 million in the year ended December 31, 2023, an increase of 324%, compared to $691,000 in year ended December 31, 2022. The increase in revenue for the year ended December 31, 2023, as compared to 2022, was primarily due to an increase of 312% in the number of Catamaran System surgical procedures.

 

Gross profit in the fourth quarter of 2023, was $559,000, or 69% of revenues, compared to a gross loss of ($207,000), or (75)% of revenues, in the comparable year ago quarter. Gross profit in the year ended December 31, 2023, was $1.2 million compared to a gross loss of ($641,000) in the year ended December 31, 2022. Gross profit and gross margin percentage improved due to higher revenue associated with the increase in the number of surgical procedures and the anticipated benefit of lower standard costs.

 

Operating losses totaled $3.1 million for the fourth quarter of 2023, compared to a loss of $7.9 million in the fourth quarter of 2022. For the year ended December 31, 2023, operating losses totaled $15.7 million compared to $18.7 million in the prior year period. Decreases in operating expenses were primarily a result of decreases in sales and marketing expenses, primarily due to the terminated agreement with a distribution partner in the prior year and decreases in general and administrative expenses.

 

Net loss was $3.1 million for the fourth quarter of 2023, compared to a loss of $7.9 million in the same period of 2022. For the year ended December 31, 2023, net loss was $15.6 million, compared to $18.9 million in the prior year. The Company expects to incur additional losses in the future.

 

2

 

 

As of December 31, 2023, cash and cash equivalents totaled $2.4 million, as compared to $2.1 million as of December 31, 2022. As of December 31, 2023, the Company had $1.2 million of outstanding debt in the form of a secured note which has been fully repaid subsequent to year end.

 

Q4 2023 Earnings Conference Call

 

Management will host an investor conference call at 4:30 p.m. ET (1:30 p.m. PT) today, Tuesday, March 12, 2024, to discuss Tenon’s fourth quarter and full year 2023 financial results, provide a corporate update, and conclude with Q&A with the Company’s covering analysts. To participate, please use the following information:

 

Date: Tuesday, March 12, 2024
Time: 4:30 p.m. Eastern time
Dial-in: 1-877-407-0792
International Dial-in: 1-201-689-8263
Webcast: TNON Conference Call

 

Please dial in at least 10 minutes before the start of the call to ensure timely participation.

 

An audio playback of the call will be available through March 26, 2024, on Tenon’s Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13744319.

 

About Tenon Medical, Inc.

 

Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran™ Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Tenon is underway with a national launch of this system to address the greatly underserved market opportunity that exists in this space. For more information, please visit www.tenonmed.com.

 

The Tenon Medical logo and Tenon Medical, are registered trademarks of Tenon Medical, Inc. Catamaran is a trademark of Tenon Medical, Inc.

 

Safe Harbor

 

This press release contains “forward-looking statements,” which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as “intends,” “estimates,” “anticipates,” “hopes,” “projects,” “plans,” “expects,” “seek,” “believes,” “see,” “should,” “will,” “would,” “target,” and similar expressions and the negative versions thereof. Such statements are based on Tenon’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our Annual Report on Form 10-K on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled “Risk Factors”. We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.

 

Investor Contact

Shannon Devine

MZ North America

203-741-8811

tenon@mzgroup.us

 

3

 

 

Tenon Medical, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(In thousands, except per share data)

 

  

Years Ended

December 31,

 
   2023   2022 
Revenue  $2,928   $691 
Cost of sales   1,687    1,332 
Gross (Loss) Profit   1,241    (641)
           
Operating Expenses          
Research and development   3,163    2,828 
Sales and marketing   6,778    7,833 
General and administrative   7,027    7,423 
Total Operating Expenses   16,968    18,084 
           
Loss from Operations   (15,727)   (18,725)
           
Other Income (Expense)          
Gain on investments   167    180 
Interest expense   (21)   (354)
Other expense, net   —    (18)
Total Other Income (Expense), net   146    (192)
Net Loss  $(15,581)  $(18,917)
Net Loss Per Share of Common Stock          
Basic and diluted  $(8.59)  $(23.62)
           
Weighted-Average Shares of Common Stock Outstanding          
Basic and diluted   1,814    801 
           
Consolidated Statements of Comprehensive Loss:          
Net loss  $(15,581)  $(18,917)
Unrealized loss on investments   16    (16)
Foreign currency translation adjustment   38    7 
Total comprehensive loss  $(15,527)  $(18,926)

 

4

 

 

Tenon Medical, Inc.

Condensed Consolidated Balance Sheets (Unaudited)

(In thousands, except share data)

 

   December 31,   December 31, 
   2023   2022 
Assets        
Current assets:        
Cash and cash equivalents  $2,428   $2,129 
Short-term investments   —    6,441 
Accounts receivable   518    228 
Inventory   554    415 
Prepaid expenses   389    134 
Total current assets   3,889    9,347 
Fixed assets, net   961    793 
Deposits   51    51 
Operating lease right-of-use asset   646    873 
Deferred offering costs   798    25 
TOTAL ASSETS  $6,345   $11,089 
           
Liabilities and Stockholders’ EQUITY          
Current liabilities:          
Accounts payable  $433   $550 
Accrued expenses   808    717 
Current portion of accrued commissions   470    1,035 
Current portion of operating lease liability   256    228 
Convertible notes payable and accrued interest, net of debt discount of $77 and $0 at December 31, 2023 and 2022, respectively   1,173    — 
Total current liabilities   3,140    2,530 
Accrued commissions, net of current portion   1,999    1,624 
Operating lease liability, net of current portion   428    683 
Total liabilities   5,567    4,837 
           
Commitments and contingencies          
Stockholders’ equity:          
Common stock, $0.001 par value; 130,000,000 shares authorized at December 31, 2023 and 2022; 2,600,311 and 1,123,680 shares issued and outstanding at December 31, 2023 and 2022, respectively   3    1 
Additional paid-in capital   55,894    45,833 
Accumulated deficit   (55,073)   (39,492)
Accumulated other comprehensive loss   (46)   (100)
Total stockholders’ equity   778    6,252 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $6,345   $11,089 

 

 

5

 

 EX-101.SCH 3 tnon-20240313.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 tnon-20240313_def.xml XBRL DEFINITION FILE EX-101.LAB 5 tnon-20240313_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, par value $0.001 per share Warrants Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 tnon-20240313_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 13, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 13, 2024
Entity File Number 001-41364
Entity Registrant Name TENON MEDICAL, INC.
Entity Central Index Key 0001560293
Entity Tax Identification Number 45-5574718
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 104 Cooper Court
Entity Address, City or Town Los Gatos
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95032
City Area Code 408
Local Phone Number 649-5760
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock, par value $0.001 per share  
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TNON
Security Exchange Name NASDAQ
Warrants  
Title of 12(b) Security Warrants
Trading Symbol TNONW
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tenonmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea0201769-8k_tenonmed.htm tnon-20240313.xsd tnon-20240313_def.xml tnon-20240313_lab.xml tnon-20240313_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0201769-8k_tenonmed.htm": { "nsprefix": "TNON", "nsuri": "http://tenonmed.com/20240313", "dts": { "inline": { "local": [ "ea0201769-8k_tenonmed.htm" ] }, "schema": { "local": [ "tnon-20240313.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "tnon-20240313_def.xml" ] }, "labelLink": { "local": [ "tnon-20240313_lab.xml" ] }, "presentationLink": { "local": [ "tnon-20240313_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://tenonmed.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0201769-8k_tenonmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0201769-8k_tenonmed.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://tenonmed.com/role/Cover" ], "auth_ref": [] }, "TNON_CommonStockParValue0.001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://tenonmed.com/20240313", "localname": "CommonStockParValue0.001PerShareMember", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, par value $0.001 per share" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "TNON_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://tenonmed.com/20240313", "localname": "WarrantsMember", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://tenonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-24-022411-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-022411-xbrl.zip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end XML 17 ea0201769-8k_tenonmed_htm.xml IDEA: XBRL DOCUMENT 0001560293 2024-03-13 2024-03-13 0001560293 TNON:CommonStockParValue0.001PerShareMember 2024-03-13 2024-03-13 0001560293 TNON:WarrantsMember 2024-03-13 2024-03-13 iso4217:USD shares iso4217:USD shares false 0001560293 8-K 2024-03-13 TENON MEDICAL, INC. DE 001-41364 45-5574718 104 Cooper Court Los Gatos CA 95032 408 649-5760 false false false false Common Stock, par value $0.001 per share TNON NASDAQ Warrants TNONW NASDAQ true false